Glucose-insulin-potassium (GIK) regimen in patients with ischemic heart disease (acute myocardial infarction) or IBD has been found to inhibit inflammatory processes and appear to be cytoprotective (70–72). This evidence concerns the gene INS and inflammatory bowel disease.